Age-related loss of skeletal muscle function; impairment of gene expression

G. Goldspink
Royal Free and University College Medical School, Royal Free Campus, London, UK

Abstract
Mechano Growth Factor (MGF) is derived from the insulin-like growth factor (IGF-I) but its sequence differs from the systemic IGF-I produced by the liver. MGF is expressed by mechanically overloaded muscle and is involved in tissue repair and adaptation. It is expressed as a pulse following muscle damage and involved in the activation of muscle satellite (stem) cells. These donate nuclei to the muscle fibers that are required for repair and for the hypertrophy processes which may have similar regulatory mechanisms. Muscles in the elderly are unable to upregulate MGF in response to exercise. This is also true in certain diseases and this helps to explain muscle loss in those conditions. There is evidence that MGF is a local tissue repair factor as well as a growth factor and that it has an important role in damage limitation and inducing repair in other post-mitotic tissues. As there is no cell replacement in these tissues there has to be an effective local cellular repair mechanism. With advancing years this seems to become deficient and there is an increased chance that the damaged cells will undergo cell death leading to progressive loss of tissue function.

Keywords: Ageing, MGF, IGF-I Gene GH, Muscle Loss, Exercise

Introduction
Sarcopenia (age-related muscle loss) is a major care problem and is becoming more serious as average life expectancy increases. The most obvious reason is that when muscle function in the elderly declines they cannot generate enough power to correct their posture quickly enough and they tend to fall over and break bones that are brittle due to osteoporosis. Muscles generate the mechanical strain that is required to make the bones healthy. Therefore when muscle activity is reduced, this exacerbates the problem and a vicious circle is established. Another perhaps less obvious function of muscle is that it acts as a metabolic store and in times of emergency it produces the proteins and metabolites required for survival. Therefore the frail elderly person who has decreased muscle mass does not survive major surgery or a traumatic accident. The muscle cachexia associated with certain diseases e.g., cancer, HIV, makes this an even greater problem as medication might have time to work if the tissue loss could be prevented.

The work of my group over the last 10 years has been to identify the factors that are involved in inducing muscle hypertrophy and loss particularly during ageing and in certain neurological conditions. As well as marked atrophy there is a loss of muscle fibers. Damage to the innervation occurs throughout life but in old age the process of collateral sprouting of the neurons appears to become less effective in repairing innervation and muscle fibers are lost1,2. As the loss of muscle function is largely related to loss of muscle it was important to determine which growth/repair factors are involved in the molecular regulation of muscle mass and why their levels or effectiveness decrease.

Cloning of MGF and other IGF-I splice variants expressed by human muscle
About 12 years ago our group set about cloning these growth factor(s) and identifying the genes involved in regulation of muscle mass. For this purpose we needed to have...
an animal model in which we could make a muscle grow rapidly. Previous work had shown that if the tibialis anterior in the mature rabbit was electrically stimulated whilst held in the stretched position by plaster cast immobilisation it increased in mass by 35% within 7 days. The mRNA in the stretch/stimulated muscles increased considerably but most of this was ribosomal RNA. Using the differential display with RT-PCR technique it was possible to detect an RNA transcript that was only expressed in the stretched/stimulated muscle and not in resting control muscles. This transcript was cloned and sequenced and when compared to sequences in the gene data bases it was seen to be derived from the insulin-like growth factor gene by alternative splicing. The terminology of the IGF-I splice variants is a problem when attempting to apply it to non hepatic tissues and therefore we named this newly discovered splice variant "mechano growth factor" (MGF) as it is expressed in response to mechanical stimulation and as it has a different downstream sequence to the liver type of IGF-I.

The sequence of the splice variant which we called mechano growth factor (MGF) proved to be extremely interesting not only because its expression was mechanosensitive but because it has a different carboxy peptide sequence. It was noted that its E domain has an insert in exon 5 that changes the reading frame. In the rat there is a 52 base insert and in the human the insert is 49 bases. Amino acids are coded for by triplets of bases and because this insert which is not a multiple of 3, is spliced into the MGF mRNA, then the downstream peptide sequence is different from that of the other IGF-I isoforms. This has important functional consequences as the different IGF-I carboxy peptide sequences are involved in the recognition of binding proteins. These stabilise and act as a time release for these growth factors. Also, in the case of MGF the carboxy peptide sequence (encoded in exons 5 and 6) acts as a different growth factor to the IGF-I receptor domain (exons 3 and 4). The E domain peptide has been shown to induce division of mononucleated myoblasts i.e. to activate the muscle satellite (stem) cells that are required for muscle hypertrophy and repair.

The systemic type of IGF-I (IGF-Ie) is expressed by many cell types including skeletal muscle. This or the mature IGF-I (IGF-I receptor domain) which is the commercially available recombinant IGF-I that has been used in a good number of in vitro and in vivo studies. The IGF-Ie cDNA has been used to produce transgenic mice and also introduce into muscle by direct injection using a viral vector. In these publications the expression has been described as muscle specific. This is misleading as muscle promoter/enhancer sequences were used in order to obtain muscle specific expression. This is compounded by the fact that when the full length cDNA of IGF-Ie was used this presumably included the carboxy peptide sequence and this recognises IGF-I
Muscle loss (sarcopenia) is one of the most obvious effects of ageing. The work of Owino et al.\textsuperscript{22} indicated that muscles in old rats, when surgically overloaded, were much less able to express MGF than those in younger animals. This was extrapolated to the human by Hameed et al.\textsuperscript{23} who showed that the muscles in elderly male volunteers when exercised, were much less able to increase MGF levels as compared to muscles of young men. None of the other parameters measured showed a marked age-related decline although it has previously been known that circulating growth hormone levels in the over 70's are much lower than those in teenagers\textsuperscript{24}. Whilst it was clear that mechanical activity plays a pivotal role in regulating local IGF-I expression in muscle, it was unclear as to whether there may be further regulation provided by hormones, notably growth hormone (GH). Some insight into this possibility was gained from the results of a recent longitudinal study where the relationship between exogenous GH administration and strength training exercise was studied in older people (age 74 ± 1 year). These were assigned to either resistance training with placebo, resistance training combined with GH administration or GH administration alone. GH administration without training did not change MGF mRNA levels when measured at 5 weeks, but significantly increased IGF-IEa levels (237%). In contrast, 5 weeks of resistance training significantly increased expression of MGF (163%) and to a lesser extent IGF-IEa (68%). However, when GH treatment was combined with exercise, MGF levels were dramatically increased (456%). These data suggest that exogenous GH administration causes an overall upregulation of transcription of the IGF-I gene prior to splicing, which results in more of the primary transcript of IGF-I. In the absence of strength training exercise, splicing is towards the IGF-IEa isoform, but when combined with the mechanical loading it splices towards the MGF isoform.

Muscle loss is a major problem in certain hereditary diseases. In dystrophic muscles it seems that there is an inability to produce MGF in response to mechanical overload\textsuperscript{25}. The systemic type of IGF-IEa is also produced by muscle, including dystrophic muscle, but MGF is apparently required to ensure muscle fiber repair and survival. Therefore the role of the IGF-I splice variant MGF seems to be very relevant to understanding the etiology and the development of possible treatment in these muscle wasting conditions as well as sarcopenia.
The role of MGF in other musculoskeletal tissues

Emerging evidence has indicated that MGF can be regarded as a cellular repair factor as well as a growth factor. Effective local tissue damage limitation and the initiation of local repair is particularly important in post-mitotic tissues such as muscle and neuronal tissue in which cell replacement is not a means of tissue repair. In these tissues, cell death must be prevented and repair initiated otherwise the ensuing cell death will result in a progressive loss of function. It was known that the myocardium expresses higher levels of IGF-I following ischemia or mechanical overload. This was shown using a general IGF-I antibody. However, recently we found that the type of IGF-I expressed in these circumstances is MGF. By transfecting cardiomyoctyes in culture using the Green Fluorescent Protein sequence attached to the 3’ end of the cDNAs of MGF and IGF-IEa, that MGF becomes rapidly localized in the nucleus whilst the IGF-IEa peptide is localized through the cytoplasm. In vivo studies of ischemia and mechanical overload indicate that MGF reduces the size of the damaged area of the myocardium and this is in accord with the finding that MGF is expressed rapidly after tissue damage and prevents apoptosis. The other type of tissue in which we have found MGF is neuronal tissue. Recent work with a Polish group has shown that MGF ameliorates the effects of ischemia to the brain where we have shown it is expressed, particularly following damage. Neuronal tissue, as well as muscle, is post-mitotic tissue, and cell replacement is not a means of tissue repair. It appears that in the CNS, which is also a post-mitotic tissue, MGF may have a similar role of ameliorating damage limitation and also possibly initiation of the repair processes. As MGF was involved in muscle repair, we thought that it may also be involved in maintaining the peripheral neurons particularly in re-innervation of muscle following damage. To investigate this we teamed up with Giorgio Terenghi’s group at the University of Manchester, who has expertise in peripheral nerve repair. The approach involved cutting the sciatic nerve and putting the two cut ends in a conduit or nerve guide with a 2mm gap between the two stumps. The conduit was filled with a gel containing MGF, or IGF-IEa or the vector only. MGF was found to induce axonal growth over the gap and to restore muscle strength to 99% of normal muscle within 3 months following complete section of the nerve. The conduit with gel only controls was effective in promoting re-innervation as about 70% of the normal muscle function was restored. This demonstrates the need for bringing the two cut ends of the nerve into juxtaposition so the proximal axons can grow down the sheaths of the distal part. Further studies have shown that one of the ways in which MGF enhances re-innervation is by causing axonal branching; and this increases the chances of re-innervating more muscle fibres.

Benefits of exercise

As far as skeletal muscle is concerned, MGF is a splice variant of the IGF-I gene that is expressed early following muscle overload and/or damage. This results in the initial activation of the skeletal muscle satellite (stem) cells which fuse with the muscle fibres and donate nuclei. In this way MGF initiates the hypertrophy process via which they adapt to the type of physical activity they are required to perform. The second phase involves the splicing of the IGF-I transcript towards the systemic or liver type or IGF-IEa which provides more of the mature IGF-I. This produces the main anabolic response that upregulates gene expression in general. The evidence indicates that this is the mechanism via which muscle mass is locally regulated and the inability to express MGF in the elderly provides an explanation for the decline in muscle function during ageing.

Exercise is also known to elevate the serum levels of IGF-I\(^{27,28}\). Not only are the muscles producing more systemic IGF-I than the liver, they are also responsible for utilizing more during intensive exercise. As the IGF-IEa and its binding proteins 3 and 5 are expressed by muscle and upregulated by exercise it means that the IGF-IEa will bind to these binding proteins. Therefore, as this form of IGF-I is expected to have more effect on the muscles that produce it than on other muscles, its action can be regarded as paracrine as well as endocrine. The uptake from the serum seems to be a consequence of the greater abundance of the specific binding protein in trained muscle. The increase in circulating IGF-I is also believed to be one of the reasons why exercise is beneficial and that general tissue maintenance has improved. There is considerable evidence that IGF-I may be involved in the maintenance of the CNS and this may be the reason why regular exercise improves cognitive function.

Acknowledgments

This work was supported by funding from the Wellcome Trust, an EC grant (PENAM) and UCL Biomedica.

References


